Tramadol
Description
A synthetic opioid analgesic, tramadol is used to treat moderate pain and can be considered a medium-strength opioid. Tramadol also has the unusual effect of being a serotonin releasing agent and a serotonin reuptake inhibitor, and as a consequence should not be taken in excess due to the risk of serotonin syndrome. Risk of seizures above 300mg doses.
Dosage
Oral
| Light | Common | Strong |
|---|---|---|
| 50-100 mg | 100-250 mg | 250-400 mg |
Duration
Oral
Safer Use
- NOTE: Tramadol has a ceiling dose, where recreational effects are not increased. Risk of seizure at doses over 300mg. Tramadol decreases the seizure threshold, use extreme caution. Dosing insufflated is ineffective.
- benzos, alcohol, and other opiates
Detection Times
| Method | Detection Window |
|---|---|
| Blood | 12–24 hours |
| Saliva | 1–2 days |
| Urine | 2–4 days |
| Hair | 1–90 days |
Note: Not detected by standard opiate immunoassay. Requires specific tramadol/extended opioid panel.
Interactions
26 known interactions with other substances.
Tramadol is well known to lower seizure threshold and psychedelics also cause occasional seizures.
This combination can cause seizures due to the lowering of the threshold by tramadol and the potential of mescaline to cause seziures.
Tramadol is well known to lower seizure threshold and NBOMes have also shown a tendency to cause severe seizures
Tramadol is well known to lower seizure threshold and psychedelics raise the risk of seizures.
Tramadol and stimulants both increase the risk of seizures.
Heavy CNS depressants, risk of seizures. Both substances potentiate the ataxia and sedation caused by the other and can lead to unexpected loss of consciousness at high doses. Place affected patients in the recovery position to prevent vomit aspiration from excess. Memory blackouts are likely.
The sedative effects of this combination can lead to dangerous respiratory depression.
Concomitant use of tramadol increases the seizure risk in patients taking other opioids. These agents are often individually epileptogenic and may have additive effects on seizure threshold during coadministration. Central nervous system- and/or respiratory-depressant effects may be additively or synergistically present
Central nervous system- and/or respiratory-depressant effects may be additively or synergistically present. Vomit aspiration a risk when passed out, lay down in recovery position if ingested.
Both substances potentiate the ataxia and sedation caused by the other and can lead to unexpected loss of consciousness at high doses. While unconscious, vomit aspiration is a risk if not placed in the recovery position. Memory blackouts are likely.
Everything in OpenMind
Track your use, check combinations and find safer use tips – even offline.